Consistently with a molecular machinery where RASSF1A, NDR2, GEF-H1 and RhoB work in concert, analysis of survival of resected early lung cancer patients from The Cancer Genome Atlas cohort, showed that low mRNA expression of RASSF1A (Additional file 2: Figure S13A), RhoB (Additional file 2: Figure S13B), and GEF-H1 (Additional file 2: Figure S13C) predict worse overall survival in NSCLC patients as high expression of NDR2 mRNA (Additional file 2: Figure S13C). The gene discussed is STK38L; the disease is non-small cell lung carcinoma.